In fact, in 2021, Placke et al. [69] analyzed PD-L1 expression in tissue samples from 156 patients diagnosed with unresectable stage III or IV melanoma prior to PD-1-based immunotherapy and compared digital PD-L1 quantification vs. physician quantification (clone 28-8; cut-off = 5%). This evidence concerns the gene CD274 and melanoma.